Case Series - (2022) Volume 7, Issue 8
Optical Coherence Tomography (OCT) can be used to detect ocular changes many of which may not be detectable using conventional viewing methods [1]. But despite its usefulness in detecting ocular pathologies, tracking pathology progression, response to treatment of the said pathologies, and making prompt and educated referrals, when necessary, its use in the optometric field in Nigeria has been limited.
This paper attempts to emphasise the importance of OCT in clinical practice using clinical case reports and provide recommendations for addressing the factors influencing its limited use by optometrists in Nigeria.
Optical Coherence Tomography (OCT) • Automated Visual Field (AVF) • Retina
The use of Optical Coherence Tomography (OCT) in the eye care field world over has exploded since its introduction over 20 years ago and its usefulness in patient management cannot be overemphasized [1]. The OCT can be used to detect early glaucomatous changes in the RNFL and GCL of the retina which might not be detected using conventional visual field analysers [2]. It can also be used in detecting maculopathies, retinopathies, optic nerve head damage due to tumours in the higher centres, etc. many of which may not be detectable using conventional retinal viewing methods (e.g., ophthalmoscopy, 90D, BIO, and fundus photography) [3]. Also, the anterior segment attachment of the OCT provides deeper insight into anterior eye segment structures to assess the anterior chamber and cornea topography, diagnose cornea pathologies, etc. [4]. But despite its usefulness, its use in the optometric field in Nigeria has been limited. Its limited use has been accredited to various factors such as cost of the equipment, cost of the procedure, the unfamiliarity of the equipment to optometrists, inability to interpret test results, etc. This study tries to highlight the importance of OCT in the practice of optometry and how it can sometimes serve as a lifesaving tool using clinical case reports. It also attempts to address the reasons behind its limited use in Nigeria and how they can be overcome for the benefit of both the patient and the practice of optometry in Nigeria and beyond.
CASE 1 Tracking response to treatment
A 54-year-old male with type 2 diabetes on medications for 10 years presented with pain and poor vision LE and seeing shadows BE for 3 months. He had no history of trauma or eye surgery. He was not on any medications for his eyes and his present glasses were gotten 5 months ago. His current fasting blood sugar (FBS) was 136 mg/dL though it had gotten as high as 400 mg/dL 6 months ago.
Ocular examination
VA (visual acuity) unaided: RE (Right Eye) 6/12 LE (Left Eye) 6/24 VA aided RE 6/12 LE 6/36.
Anterior segment: no abnormality detected BE (Both Eyes)
Lens: 1+ Nuclear Sclerosis BE
Fundus: C/D (Cup to Disc) ratio 0.3 BE, macular oedema LE
IOP (Intraocular Pressure): RE 12 mmHg LE 10 mmHg
Further ocular exams
CCT (Central Cornea Thickness): RE 551 µm (-0.4) LE 567 µm (-1.5)
AVF (Automated Visual Field): Unremarkable with generalized reduced sensitivity consistent with nuclear sclerosis BE.
Fundus photo: Blot haemorrhage, hard exudate, microaneurysm, refractile bodies BE
OCT (Optical Coherence Tomography): Clinically significant macular oedema BE, blot haemorrhage, hard exudate, microaneurysm BE.
Diagnosis: Diabetic retinopathy with clinically significant macular oedema BE.
Management: 3 doses per eye of Intravitreal avastin injection at monthly intervals (Figure 1).
Figure 1: Initial visit OCT macular scan BE
Follow up visits
1-month post 1st Avastin dose
FBS: 148 mg/dl
VA unaided: RE 6/12 LE 6/18
IOP: RE 12 mmHg LE 14 mmHg (Figure 2).
Figure 2: 1-month post 1st Avastin dose OCT macular scan BE
1-month post 2nd Avastin dose
FBS: 83mg/dl
VA unaided: RE 6/9 LE 6/24 (Figure 3).
Figure 3: 1-month post 2nd Avastin dose OCT macular scan BE
1-month post 3rd Avastin dose
VA unaided: RE 6/12 LE 6/24
VA aided: RE 6/9 LE 6/18
IOP: RE 14 mmHg LE 14 mmHg (Figure 4).
Figure 4: 1-month post 3rd Avastin dose OCT macular scan BE
Importance of OCT in this case
CASE 2 Detecting early glaucoma changes
A 56-year-old male with a family history of glaucoma presented with difficulty reading with present glasses and cloudy vision for 1 year. He also had complaints of occasional headaches and mild photophobia BE. There was no history of trauma or eye surgery.
Ocular examination
VA unaided RE: 6/12 LE 6/12 N8
VA aided RE: 6/5 LE 6/6 N5.
Anterior segment: no abnormality detected BE
Lens: 1+ Nuclear sclerosis BE
Fundus: RE pale cupped disc C/D ratio 0.7 LE pale cupped C/D ratio 0.8
IOP: RE 19 mmHg LE 17mmHg
Further ocular exams
Patient opted to only carry out the AVF test
AVF: RE mild blind spot enlargement LE mild blind spot enlargement
Diagnosis: Glaucoma suspect
Management: Recommended carrying out all pending tests ASAP (Figure 5).
Figure 5: AVF result BE from initial visit
Follow up visit
He later presented 4 years after the first visit with complaints of cloudy vision for 2 years.
Ocular examination
VA unaided: RE 6/18 LE 6/12 VA aided RE 6/12 LE 6/18.
Anterior segment: no abnormality detected BE
Pupils: RE Normal LE subtle RAPD (Relative Afferent Pupillary Defect) detected
Lens: 1+ Nuclear Sclerosis BE
Fundus: RE poor details LE mild pallor C/D ratio 0.6
IOP: RE 23 mmHg LE 25 mmHg.
Further ocular exams
CCT: RE 522 µm (+1.6) LE 525 µm (+1.4)
Fundus photo: cupped discs BE
AVF: RE moderate superior and inferior arcuate scotoma LE extensive superior and inferior arcuate scotoma viz a viz tunnel vision.
OCT: RE mild thinning on GCL (Ganglion Cell Layer) normal RNFL (Retina Nerve Fibre Layer) LE significant thinning in GCL and RNFL especially inferiorly.
Diagnosis: Moderate glaucoma Management: gutt latanoprost nocte BE, gutt azopt 12 hly (Figure 6-8)
Figure 6: AVF result BE from 2nd visit.
Figure 7: OCT RNFL scan BE from 2nd visit
Figure 8: OCT RNFL and GCL scan BE from 2nd visit
Importance of OCT in this case
CASE 3 Diagnosis of neurological conditions
A 57-year-old female presented with eye aches and headaches (frontal). There was no history of trauma or eye surgery.
Ocular examination
VA unaided: RE 6/18 LE 6/9
VA aided: RE 6/12 LE 6/9
Anterior segment: no abnormality detected BE
Lens: 1+ Nuclear Sclerosis BE 1+PSC (Posterior subcapsular) LE
Fundus: C/D ratio 0.35 BE, refractile bodies RE IOP: RE 15 mmHg LE 16 mmHg
Further ocular exams
AVF: was not done as the patient was uncooperative during the process and was not keen on carrying out the test
CCT: RE 548 µm (-0.2) LE 557 µm (-0.9)
Fundus photo: normal macular BE
OCT: RE mild RNFL thinning C/D 0.68 LE normal RNFL C/D 0.57
Diagnosis: Early glaucoma
Management: Gutt dozolamide bd BE (Figure 9).
Figure 9: . OCT RNFL scan BE from initial visit
1st follow-up visit
She presented a year after the first visit with complaints of blurry vision, and persistent left-sided headaches.
Ocular examination
VA unaided: R 6/9 L 6/18 VA aided R 6/9 L 6/12
IOP: RE 18 mmHg LE 16 mmHg
Lens: 1+ Nuclear Sclerosis BE 1+PSC LE Dull Macular Reflex LE
Fundus: C/D ratio 0.35 BE
Further ocular exams
AVF: not done on patient’s request
OCT: severe RNFL thinning in all quadrants BE
Diagnosis: Normal-Tension Glaucoma
Management: to do MRI, continue all medications, AVF to be done
2nd follow-up visit
The patient came with the MRI results 2 weeks after the last visit. Results were indicative of a pituitary macroadenoma. She was referred to a neurosurgeon (Figure 10).
Figure 10: OCT RNFL scan BE from a 1st follow-up visit
Importance of OCT in this case
Early detection of a brain lesion in a patient uncooperative for AVF.
CASE 4 Identifying false glaucoma diagnosis
A 7-year-old male with a family history of glaucoma presented with a history of blurred distant vision for 1 year. He was experiencing pain, mild photophobia, occasional redness, and mild foreign body sensation BE. There was no history of trauma or surgery and he had never used glasses nor he was on medication.
Ocular examination
VA Unaided: RE 6/9 LE 6/9 Anterior
segment: no abnormality detected BE
Fundus: RE 0.5 LE 0.4 large cup large disc BE
Subjective refraction: R -1.00 6/5 L -0.25 6/5
Cycloplegic refraction: R +0.75 L +0.75
Post cycloplegic refraction: R +0.50 6/5 L +0.50 6/5
Diagnosis: Hyperopia
Management: To get glasses
Follow up visit
The mother of the patient said she took the patient to another Eye center and was told he had glaucoma. She wanted a second opinion on their report. The medical report from the other center indicated IOP was RE 11 mmHg LE 10 mmHg. The patient was uncooperative for AVF and was eventually placed on gutt timoptol bd BE by the other eye center.
Ocular examination
Unaided: VA RE 6/18 LE 6/12
Aided VA: RE 6/9 LE 6/5
Anterior segment: no abnormality detected BE
Fundus: RE C/D ratio 0.5 LE C/D ratio 0.4 large cups large disc BE
Further ocular exams
AVF: Unable to do AVF as the patient was sleepy
Fundus photo: Healthy neuroretinal rim BE, no notching, no peripapillary atrophy, Positive ISNT, and healthy macular BE.
OCT: No RNFL defects seen, no GCL defects seen
Diagnosis: Normal eyes Plan: Stop Timoptol, continue with present glasses, IOP check in 1 month (Figure 11).
Figure 11: OCT RNFL scan BE from a follow-up visit
Importance of OCT in this case
The OCT has proven to be a valuable tool in the hands of other eye care professionals and Nigerian optometrists in both the private and public sectors should be able to take advantage of such a tool for the benefit of the patient. Several strategies can be adopted to increase its usage by addressing the reasons behind its limited use. They include
The OCT is an invaluable tool in the arsenal of eye care practitioners especially optometrists as they are usually the first point of call for persons accessing eye care services and thus might be the first clinicians to detect sight and even life-threatening conditions. Having the use of the OCT at their disposal will be a plus for the healthcare system by aiding early detection and correct diagnosis and management of ocular conditions.
[Google Scholar] [Cross Ref]
Citation: Adomi OE. The Role of OCT in Optometric Practice in Nigeria. Med Rep Case Stud. 2022, 07 (8),001-006.
Received: 24-Jul-2022, Manuscript No. MRCS-22-70140; Editor assigned: 26-Jul-2022, Pre QC No. MRCS- 22- 70140 (PQ); Reviewed: 05-Aug-2022, QC No. MRCS- 22-70140 (Q); Revised: 08-Aug-2022, Manuscript No. MRCS- 22-[70140 (R); Published: 10-Aug-2022, DOI: 10.4172/2572 5130.22.7(8).1000210
Copyright: ©2022 Adomi OE. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.